Ligand Pharmaceuticals held its 2023 Annual Meeting of Stockholders, where the election of directors, ratification of Ernst & Young LLP as the independent registered public accounting firm, approval of executive officer compensation, and frequency of advisory vote on executive officer compensation were discussed and approved.